Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward

Juliet E Bryant; Andrew S Azman; Matthew J Ferrari; Benjamin F Arnold; Maciej F Boni; Yap Boum; Kyla Hayford; Francisco J Luquero; Michael J Mina; Isabel Rodriguez-Barraquer; Joseph T Wu; Djibril Wade; Guy Vernet; Daniel T Leung

doi:10.1126/sciimmunol.abc6347

Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward

Sci Immunol. 2020 May 19;5(47):eabc6347. doi: 10.1126/sciimmunol.abc6347.

Authors

Juliet E Bryant¹, Andrew S Azman^{2

3}, Matthew J Ferrari⁴, Benjamin F Arnold⁵, Maciej F Boni⁴, Yap Boum⁶, Kyla Hayford², Francisco J Luquero⁷, Michael J Mina⁸, Isabel Rodriguez-Barraquer⁹, Joseph T Wu¹⁰, Djibril Wade¹¹, Guy Vernet¹², Daniel T Leung¹³

Affiliations

¹ Laboratory of Emerging Pathogens, Fondation Mérieux, Lyon, France.
² Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
³ Médecins Sans Frontières, Geneva, Switzerland.
⁴ Department Biology, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA, USA.
⁵ Francis I Proctor Foundation, University of California San Francisco, CA, USA.
⁶ Epicentre, Yaounde, Cameroon.
⁷ Epicentre, Paris, France.
⁸ Departments of Epidemiology and of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA USA.
⁹ School of Medicine, University of California San Francisco, CA, USA.
¹⁰ WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
¹¹ IRESSEF (Institut de Recherche en Santé, de Surveillance Épidémiologique et de Formation), Dakar, Senegal.
¹² Institut Pasteur de Bangui, Bangui, Central African Republic.
¹³ Division of Infectious Diseases, University of Utah School of Medicine, Salt Lake City, UT, USA daniel.leung@utah.edu.

PMID: 32430309
DOI: 10.1126/sciimmunol.abc6347

Abstract

Serological testing for SARS-CoV-2 has enormous potential to contribute to COVID-19 pandemic response efforts. However, the required performance characteristics of antibody tests will critically depend on the use case (individual-level vs. population-level).

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral / analysis
Betacoronavirus / immunology
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques / methods*
Coronavirus Infections / diagnosis
Coronavirus Infections / immunology
Epidemiological Monitoring
Humans
Pandemics
Pneumonia, Viral / immunology
SARS-CoV-2

Substances

Antibodies, Viral